Liquid Biopsy Market Overview
The Liquid Biopsy Market focuses on advanced, minimally invasive diagnostic technologies that analyze biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other molecular materials from biological fluids. Liquid biopsy is increasingly used for cancer diagnosis, treatment monitoring, recurrence monitoring, precision medicine, and clinical research. The technology provides healthcare professionals with a less invasive alternative to conventional tissue biopsies and supports real-time insights into disease progression and treatment response. According to Market Research Future, the Global Liquid Biopsy Market was valued at USD 9.1 billion in 2024 and is projected to reach USD 27.34 billion by 2035, registering a CAGR of 10.52% during 2025–2035.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/710
Market Drivers
Rising Incidence of Cancer
The increasing global prevalence of cancer is one of the major factors driving the demand for liquid biopsy technologies. As cancer cases continue to increase, healthcare providers require diagnostic methods that can support early detection, molecular profiling, treatment selection, and ongoing disease monitoring. Liquid biopsy enables the analysis of tumor-related biomarkers through minimally invasive sample collection, supporting its expanding role in oncology.
Growing Demand for Non-Invasive Diagnostics
Liquid biopsy provides a less invasive alternative to traditional tissue biopsy procedures. Blood-based testing can be performed repeatedly, making it useful for monitoring disease progression and treatment response. The growing preference for patient-friendly diagnostic procedures is therefore contributing to the adoption of liquid biopsy technologies across healthcare systems.
Increasing Adoption of Precision Medicine
The growing emphasis on personalized medicine is another important market driver. Liquid biopsy can identify genetic alterations and molecular biomarkers that help physicians select appropriate targeted therapies. Its ability to provide molecular information without requiring repeated invasive tissue collection is strengthening its importance in precision oncology.
Technological Advancements in Genomic Testing
Advancements in next-generation sequencing, digital PCR, microfluidics, circulating tumor cell analysis, and other molecular technologies are improving the sensitivity and capabilities of liquid biopsy. NGS currently represents the leading technology segment, accounting for 61% of the market in 2024.
Increasing Clinical Adoption
Healthcare providers are increasingly adopting liquid biopsy for cancer diagnosis, treatment monitoring, and recurrence assessment. Growing clinical evidence, improved testing capabilities, and greater awareness of minimally invasive molecular diagnostics are supporting wider implementation across hospitals and diagnostic laboratories.
Market Challenges
High Cost of Advanced Testing
The cost associated with sophisticated sequencing platforms, molecular assays, laboratory infrastructure, and specialized personnel can restrict the adoption of liquid biopsy technologies, particularly in developing healthcare markets.
Regulatory and Clinical Validation Challenges
Liquid biopsy tests often require extensive clinical validation to establish analytical performance, clinical utility, and reliability. Differences in regulatory requirements across countries can also create challenges for manufacturers seeking international commercialization.
Limited Standardization
Variations in testing methodologies, sample preparation, biomarker detection, and interpretation can create difficulties in standardizing liquid biopsy procedures. Greater standardization is important for broader integration into routine clinical practice.
Technical Limitations
The concentration of certain biomarkers, including circulating tumor DNA and circulating tumor cells, may be low in some patients. This can make detection technically challenging and increase the importance of highly sensitive analytical technologies.
Competition from Conventional Diagnostic Methods
Traditional tissue biopsy, imaging technologies, and other established diagnostic procedures continue to compete with liquid biopsy. Physicians may continue using conventional approaches when tissue samples are required for comprehensive pathological evaluation.
Browse In-depth Market Research Report on Liquid Biopsy Market:
https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710
Market Segmentation
By Application:
Oncology: Oncology is the leading application segment, accounting for 66% of the market in 2024. Liquid biopsy is increasingly used for cancer detection, molecular profiling, treatment selection, therapy monitoring, and recurrence assessment.
Non-Oncology: Liquid biopsy technologies are also being investigated and applied in several non-oncology applications, expanding the potential addressable market.
Prenatal Testing: Prenatal testing represents an important emerging application, supported by the increasing adoption of non-invasive testing technologies.
Infectious Disease: Liquid biopsy approaches are being explored for detecting biomarkers associated with infectious diseases.
Transplantation: Molecular testing can support transplant monitoring and the assessment of biological changes following transplantation.
By Sample Type:
Blood: Blood is the dominant sample type, accounting for 69% of the market in 2024. Its minimally invasive collection and suitability for detecting circulating tumor DNA, circulating tumor cells, and other biomarkers make it widely used.
Urine: Urine is an emerging sample type because collection is convenient, non-invasive, and suitable for research into cancer detection and disease monitoring.
Saliva: Saliva offers another convenient biological sample for molecular and biomarker analysis.
Pleural Fluid: Pleural fluid can provide valuable biological information for selected cancer-related applications.
Cerebrospinal Fluid: Cerebrospinal fluid is used in specialized applications where molecular information from the central nervous system is required.
By Technology:
Next Generation Sequencing: NGS held the largest technology share at 61% in 2024. It enables comprehensive genomic profiling and identification of multiple genetic alterations from circulating biomarkers.
Digital PCR: Digital PCR provides highly sensitive and quantitative detection of specific genetic alterations and is expected to experience strong adoption.
Microfluidics: Microfluidic technologies support efficient processing and isolation of biological components from small sample volumes.
Exosome Isolation: Exosome-based technologies are being developed to identify disease-related molecular information contained within extracellular vesicles.
Circulating Tumor Cell Technology: CTC technologies enable the isolation and analysis of tumor cells circulating within the bloodstream.
By End Use:
Hospitals: Hospitals represent the leading end-user segment, accounting for 58% of the market in 2024. Their oncology departments, diagnostic infrastructure, and specialized personnel support extensive liquid biopsy utilization.
Diagnostic Laboratories: Diagnostic laboratories are experiencing strong growth as healthcare providers increasingly rely on specialized molecular testing services.
Research Institutes: Research institutions use liquid biopsy technologies for biomarker discovery, cancer research, drug development, and clinical studies.
Pharmaceutical Companies: Pharmaceutical companies utilize liquid biopsy for companion diagnostics, clinical trials, treatment monitoring, and precision medicine research.
Regional Insights
North America
North America dominated the Liquid Biopsy Market in 2024, accounting for more than 49.45% of global revenue and generating approximately USD 4.5 billion. The region benefits from advanced healthcare infrastructure, high cancer prevalence, strong research activity, and the presence of major liquid biopsy companies. The U.S. remains a major contributor, with companies such as Guardant Health, Exact Sciences, and GRAIL driving innovation.
Europe
Europe represented the second-largest regional market, with a market value of USD 2.73 billion and approximately 30% share in 2024. Increasing awareness of early cancer detection, adoption of personalized medicine, healthcare investment, and regulatory support are contributing to market development across countries such as Germany, France, and the UK.
Asia-Pacific
Asia-Pacific is experiencing significant growth, supported by increasing healthcare expenditure, rising cancer incidence, improving diagnostic infrastructure, and growing awareness of early detection. The region was valued at approximately USD 1.82 billion in 2024. China, Japan, and India are among the important markets contributing to regional expansion.
Middle East & Africa
The Middle East and Africa represent an emerging market for liquid biopsy. Increasing awareness of cancer screening and investments in healthcare technologies are creating growth opportunities. However, limited healthcare infrastructure, access to advanced molecular testing, and regulatory challenges may restrict faster adoption.
Key Players
Guardant Health
Exact Sciences
GRAIL
Freenome
Biocept
Sysmex Corporation
Roche Diagnostics
Qiagen
Thermo Fisher Scientific
Illumina
These companies are competing through technological innovation, product development, strategic collaborations, genomic testing capabilities, and expansion of liquid biopsy applications.
Future Outlook
The Liquid Biopsy Market is expected to experience strong growth through 2035 as healthcare systems increasingly prioritize early cancer detection, precision medicine, and minimally invasive diagnostic approaches. According to MRFR, the market is projected to grow from USD 10.06 billion in 2025 to USD 27.34 billion by 2035, registering a CAGR of 10.52% during 2025–2035.
Future opportunities include the development of advanced liquid biopsy platforms, AI-supported molecular analysis, broader applications in early cancer detection, improved treatment monitoring, companion diagnostics, and expansion into emerging markets. Strategic partnerships between diagnostic companies, pharmaceutical companies, hospitals, and research institutions are also expected to support market development.
By 2035, liquid biopsy is expected to become an increasingly important component of modern cancer diagnostics, particularly as sequencing technologies, biomarker detection, and personalized treatment approaches continue to advance.
Gain a competitive edge with insightful market reports:
About Market Research Future:
Market Research Future (MRFR) is a global market research company that provides market intelligence, analysis, and forecasting across diverse industries and geographic markets. Its research covers products, services, technologies, applications, end users, and market players at global, regional, and country levels, helping clients understand market trends, competitive landscapes, growth opportunities, and emerging technologies.
Follow Us: LinkedIn | Twitter
Contact:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
